ArticleThe open AIDS journal2009
Vaccines, virucides and drugs against HIV/AIDS: hopes and optimisms for the future.
Article in The open AIDS journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 16 citations in OpenAlex.
- Advances in Antiviral Material Development.ChemPlusChem · 2020Article
- Current perspectives regarding the application and incorporation of silver nanoparticles into dental biomaterials.Clujul medical (1957) · 2018Review
- Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.Journal of experimental pharmacology · 2013Article
- Current perspectives of nanoparticles in medical and dental biomaterials.Journal of biomedical research · 2012Article
- Mode of antiviral action of silver nanoparticles against HIV-1.Journal of nanobiotechnology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 25 million lives have been claimed by AIDS and 33.2 million people are estimated to have HIV, the majority of which are living in the underdeveloped countries. Failed tests on vaccines, virucides and complete virus eradication have caused scientists to refocus on the basic questions of what makes an effective HIV immune response. The "gloom" over disappointing research results on vaccine development and virucides "threatens to overshadow more positive" HIV/AIDS-related news, such as findings that male circumcision might reduce the likelihood of HIV transmission and that giving antiretroviral drugs to "high-risk" HIV-negative people (pre-exposure prophylaxis) could help protect them from infection. Something like pre-exposure prophylaxis has a good chance of becoming available before we have a 100% efficacious vaccine. The future in the field of HIV/AIDS will be much brighter if global research is appropriately coordinated and sufficient funds are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.